Internal comorbidities and complications of multiple sclerosis therapy - don't be caught off guard

• Published in: Vnitřní lékar̆stvĭ Vol. 69; no. 5; p. 294
• Main Authors: Šťastná, Dominika, Seňavová, Jana, Andělová, Michaela, Menkyová, Ingrid, Pšenička, Otakar, Horáková, Dana
• Format: Journal Article
• Language: Czech; English
• Published: Czech Republic 01-10-2023
• Subjects: Chronic Disease; Comorbidity; Humans; Multiple Sclerosis - complications; Multiple Sclerosis - drug therapy; Multiple Sclerosis - epidemiology; Risk Factors; Young Adult; autoimmune diseases; drug-drug interactions; comorbidities; Drug interactions; multiple sclerosis; adverse effects; disease -modifying therapies; side effects
• ISSN: 0042-773X
• DOI: 10.36290/vnl.2023.058

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system, mainly affecting young adults. Factors positively influencing its course include early antiinflammatory treatment and the influencing of other comorbidities. The most common comorbidities occurring in MS patients with a higher frequency than in the general population are neurological, psychiatric, cardiovascular, metabolic and autoimmune. Just as comorbidity compensation affects the course of MS, in some cases, MS decompensation is associated with a worse course of associated diseases. Due to common risk factors and partially shared immunopathogenesis, treatment covering multiple conditions can be used, especially for some autoimmune diseases. On the other hand, some drugs may potentiate the development of other autoimmunity or disorder. A special topic is the side effects and complications of treatment (especially infections and malignancies) of disease-modifying therapies used in patients with MS. However, the potential treatment discontinuation carries significant risks and should always be discussed with the MS specialist. Therefore, close interdisciplinary collaboration is crucial.